Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation

Higgins, E., Al Shehri, T., McAleer, M. A., Conlon, N., Feighery, C., Lilic, D., & Irvine, A. D. (2015). Use of ruxolitinib to successfully treat chronic mucocutaneous candidiasis caused by gain-of-function signal transducer and activator of transcription 1 (STAT1) mutation. Journal of Allergy and Clinical Immunology, 135(2), 551-553.e3. https://doi.org/10.1016/j.jaci.2014.12.1867